<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03299738</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-C2017006</org_study_id>
    <nct_id>NCT03299738</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL</brief_title>
  <official_title>A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-cell Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy
      of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Pre-Treatment (Cell
      Product Preparation, Lymphodepleting Chemotherapy), Treatment and Follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Vital signs, physical examination, clinical laboratory tests, incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Refractory or Relapsed B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-CAR011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-CAR011</intervention_name>
    <description>Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>
    <arm_group_label>C-CAR011</arm_group_label>
    <other_name>Anti-CD19 Chimeric Antigen Receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteered to participate in this study and signed informed consent

          2. Age 18-70 years old, male or female

          3. Relapse or refractory B cell non-Hodgkin's lymphoma

               -  1. Histologically diagnosed as DLBCL (including PMBCL) or follicular lymphoma
                  (grade Ⅲb) according to the NCCN non-Hodgkin's lymphoma Clinical Practice
                  Guidelines (2017 Version 1)

                    -  Progressive disease after the last standard chemotherapy regimens per the
                       IWG Response Criteria (1999)

                    -  Stable disease after the last standard chemotherapy regimens (at least 4
                       cycles of first-line therapy or 2 cycles of later-line therapy) per the IWG
                       Response Criteria (1999)

                    -  Relapse or progressive disease within 12 months after autologous stem cell
                       transplantation (SCT)

               -  2. Follicular lymphoma (stage Ⅲ-Ⅳ) (gradeⅠ-Ⅲa)

                    -  At least 2 combination chemotherapy regimens (excluding single agent
                       monoclonal antibody)

                    -  Relapse or progressive disease within 1 year after last chemotherapy
                       regimens

               -  3. Mantle cell lymphoma

                    -  Relapse after 1st CR or persistent disease, and not eligible or appropriate
                       for SCT

                    -  Relapse or progressive disease within 1 year after the last chemotherapy
                       regimens

                    -  Relapse or progressive disease within 12 months after autologous SCT

          4. All subjects must have received anti-CD20 monoclonal antibody (unless tumor is
             CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN
             non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1)

          5. At least one measurable lesion per revised IWG Response Criteria (the longest diameter
             of the tumor ≥ 1.5 cm)

          6. Expected survival ≥ 12 weeks

          7. ECOG score 0-1

          8. Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography)

          9. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%
             on room air

         10. At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy)
             prior to leukapheresis, or at least 4 weeks from monoclonal antibody therapy prior to
             CAR T cell therapy

         11. No contraindications of leukapheresis

         12. Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative, and must agree to take effective contraceptive measures during the trial

        Exclusion Criteria:

          1. History of allergy to cellular products

          2. Laboratory tests: absolute neutrophil count &lt; 1.0 × 10^9 /L, platelet count &lt; 50 ×
             10^9 /L, serum albumin &lt; 30 g/L, serum bilirubin &gt; 1.5 ULN, serum creatinine &gt; ULN,
             ALT/AST &gt; 3 ULN

          3. History of CAR T cell therapy or any other genetically modified T cell therapy

          4. Relapse after allogeneic hematopoietic stem cell transplantation

          5. Active infections that require treatment (uncomplicated urinary tract infections and
             bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal
             treatment are permitted

          6. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as
             acquired or congenital immune deficiency diseases, including but not limited to HIV
             infection

          7. Class III or IV heart failure according to the NYHA Heart Failure Classifications

          8. QT interval prolongation ≥ 450 ms

          9. History of epilepsy or other central nervous system disorders

         10. Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging

         11. History of other primary cancers, with the following exceptions

               -  Excisional non-melanoma (e.g. cutaneous basal cell carcinoma)

               -  Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer)

         12. Autoimmune diseases that require treatment, immune deficiency diseases or other
             diseases that require immunosuppressive therapy

         13. Used of systemic steroids within two weeks (using inhaled steroids is an exception)

         14. Women who are pregnant or lactating, or who have breeding intent in 6 months

         15. Participated in any other clinical trial within three months

         16. Any situation that investigators believe the risk of the subjects is increased or
             results of the trial are disturbed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huilai Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huilai Zhang</last_name>
    <phone>+86-022-23340123</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huilai Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

